English
简体中文
Total: £ 56.28
Published Date: 2026-04-02 | Pages: 122 | Tables: 137 | Pharma & Healthcare
The global Follicular Lymphoma Drugs market was valued at US$ 2103 million in 2025 and is anticipated to reach US$ 3442 million by 2032, at a CAGR of 7.4% from 2026 to 2032.
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The follicular lymphoma drugs market is primarily driven by the increasing prevalence of follicular lymphoma (FL), a common and slow-growing form of non-Hodgkin lymphoma. As the global population ages, the incidence of FL is expected to rise, which boosts demand for effective treatments. Additionally, recent advancements in targeted therapies, including monoclonal antibodies like rituximab and the development of novel small molecules, have significantly improved patient outcomes and survival rates. The growing adoption of combination therapies, such as chemotherapy paired with targeted treatments or immunotherapies, has further expanded treatment options and contributed to the market's growth. The emergence of personalized medicine also enhances the potential for more tailored, effective therapies.
On the other hand, the follicular lymphoma drugs market faces challenges, including the high cost of cutting-edge therapies. Treatments such as CAR-T cell therapy and novel biologics, while effective, can be expensive and limit patient access, particularly in lower-income regions. Additionally, although FL is typically slow-growing, it is also highly recurrent, requiring long-term management and monitoring, which can strain healthcare systems. The risk of resistance to existing therapies, along with concerns over the long-term side effects of certain treatments, further complicates the landscape. Regulatory hurdles for the approval of new drugs, along with the need for ongoing research into optimizing treatment regimens, present further challenges in meeting the diverse needs of FL patients.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
This report delivers a comprehensive overview of the global Follicular Lymphoma Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Follicular Lymphoma Drugs. The Follicular Lymphoma Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Follicular Lymphoma Drugs market comprehensively. Regional market sizes by Type, by Administration Route, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Follicular Lymphoma Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Administration Route, and by region.
Market Segmentation
By Company
Roche
Gilead Sciences
Beigene
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Pfizer
Novartis
Bristol-Myers Squibb
JW Therapeutics
FOSUNKite
Segment by Type
Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others
Segment by Administration Route
Injection
Oral
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Administration Route, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Follicular Lymphoma Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Administration Route, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Anti-CD20 mAbs
1.2.3 Chemotherapy Agents
1.2.4 Kinase Inhibitor
1.2.5 Others
1.3 Market by Administration Route
1.3.1 Global Follicular Lymphoma Drugs Market Growth by Administration Route: 2021 vs 2025 vs 2032
1.3.2 Injection
1.3.3 Oral
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Follicular Lymphoma Drugs Market Perspective (2021–2032)
2.2 Global Follicular Lymphoma Drugs Growth Trends by Region
2.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2021–2026)
2.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2027–2032)
2.3 Follicular Lymphoma Drugs Market Dynamics
2.3.1 Follicular Lymphoma Drugs Industry Trends
2.3.2 Follicular Lymphoma Drugs Market Drivers
2.3.3 Follicular Lymphoma Drugs Market Challenges
2.3.4 Follicular Lymphoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Follicular Lymphoma Drugs Players by Revenue
3.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2021–2026)
3.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2021–2026)
3.2 Global Top Follicular Lymphoma Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Follicular Lymphoma Drugs Revenue
3.4 Global Follicular Lymphoma Drugs Market Concentration Ratio
3.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2025
3.5 Global Key Players of Follicular Lymphoma Drugs Head Offices and Areas Served
3.6 Global Key Players of Follicular Lymphoma Drugs, Products and Applications
3.7 Global Key Players of Follicular Lymphoma Drugs, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Follicular Lymphoma Drugs Breakdown Data by Type
4.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2021–2026)
4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2027–2032)
5 Follicular Lymphoma Drugs Breakdown Data by Administration Route
5.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2021–2026)
5.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2027–2032)
6 North America
6.1 North America Follicular Lymphoma Drugs Market Size (2021–2032)
6.2 North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Follicular Lymphoma Drugs Market Size by Country (2021–2026)
6.4 North America Follicular Lymphoma Drugs Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Follicular Lymphoma Drugs Market Size (2021–2032)
7.2 Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Follicular Lymphoma Drugs Market Size by Country (2021–2026)
7.4 Europe Follicular Lymphoma Drugs Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2021–2032)
8.2 Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2021–2026)
8.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Follicular Lymphoma Drugs Market Size (2021–2032)
9.2 Latin America Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Follicular Lymphoma Drugs Market Size by Country (2021–2026)
9.4 Latin America Follicular Lymphoma Drugs Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2021–2032)
10.2 Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2021–2026)
10.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Follicular Lymphoma Drugs Introduction
11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.1.5 Roche Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.2.5 Gilead Sciences Recent Development
11.3 Beigene
11.3.1 Beigene Company Details
11.3.2 Beigene Business Overview
11.3.3 Beigene Follicular Lymphoma Drugs Introduction
11.3.4 Beigene Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.3.5 Beigene Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Follicular Lymphoma Drugs Introduction
11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.4.5 Bayer Recent Development
11.5 Secura Bio
11.5.1 Secura Bio Company Details
11.5.2 Secura Bio Business Overview
11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction
11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.5.5 Secura Bio Recent Development
11.6 Epizyme
11.6.1 Epizyme Company Details
11.6.2 Epizyme Business Overview
11.6.3 Epizyme Follicular Lymphoma Drugs Introduction
11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.6.5 Epizyme Recent Development
11.7 Eisai
11.7.1 Eisai Company Details
11.7.2 Eisai Business Overview
11.7.3 Eisai Follicular Lymphoma Drugs Introduction
11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.7.5 Eisai Recent Development
11.8 Acrotech Biopharma
11.8.1 Acrotech Biopharma Company Details
11.8.2 Acrotech Biopharma Business Overview
11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction
11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.8.5 Acrotech Biopharma Recent Development
11.9 Teva
11.9.1 Teva Company Details
11.9.2 Teva Business Overview
11.9.3 Teva Follicular Lymphoma Drugs Introduction
11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.9.5 Teva Recent Development
11.10 Eagle Pharmaceuticals
11.10.1 Eagle Pharmaceuticals Company Details
11.10.2 Eagle Pharmaceuticals Business Overview
11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction
11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.10.5 Eagle Pharmaceuticals Recent Development
11.11 MundiPharma
11.11.1 MundiPharma Company Details
11.11.2 MundiPharma Business Overview
11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction
11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.11.5 MundiPharma Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Details
11.12.2 Pfizer Business Overview
11.12.3 Pfizer Follicular Lymphoma Drugs Introduction
11.12.4 Pfizer Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.12.5 Pfizer Recent Development
11.13 Novartis
11.13.1 Novartis Company Details
11.13.2 Novartis Business Overview
11.13.3 Novartis Follicular Lymphoma Drugs Introduction
11.13.4 Novartis Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.13.5 Novartis Recent Development
11.14 Bristol-Myers Squibb
11.14.1 Bristol-Myers Squibb Company Details
11.14.2 Bristol-Myers Squibb Business Overview
11.14.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Introduction
11.14.4 Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.14.5 Bristol-Myers Squibb Recent Development
11.15 JW Therapeutics
11.15.1 JW Therapeutics Company Details
11.15.2 JW Therapeutics Business Overview
11.15.3 JW Therapeutics Follicular Lymphoma Drugs Introduction
11.15.4 JW Therapeutics Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.15.5 JW Therapeutics Recent Development
11.16 FOSUNKite
11.16.1 FOSUNKite Company Details
11.16.2 FOSUNKite Business Overview
11.16.3 FOSUNKite Follicular Lymphoma Drugs Introduction
11.16.4 FOSUNKite Revenue in Follicular Lymphoma Drugs Business (2021–2026)
11.16.5 FOSUNKite Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Anti-CD20 mAbs
Table 3. Key Players of Chemotherapy Agents
Table 4. Key Players of Kinase Inhibitor
Table 5. Key Players of Others
Table 6. Global Follicular Lymphoma Drugs Market Size Growth by Administration Route (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Follicular Lymphoma Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Follicular Lymphoma Drugs Market Size by Region (US$ Million), 2021–2026
Table 9. Global Follicular Lymphoma Drugs Market Share by Region (2021–2026)
Table 10. Global Follicular Lymphoma Drugs Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Follicular Lymphoma Drugs Market Share by Region (2027–2032)
Table 12. Follicular Lymphoma Drugs Market Trends
Table 13. Follicular Lymphoma Drugs Market Drivers
Table 14. Follicular Lymphoma Drugs Market Challenges
Table 15. Follicular Lymphoma Drugs Market Restraints
Table 16. Global Follicular Lymphoma Drugs Revenue by Players (US$ Million), 2021–2026
Table 17. Global Follicular Lymphoma Drugs Market Share by Players (2021–2026)
Table 18. Global Top Follicular Lymphoma Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Follicular Lymphoma Drugs Revenue, 2025
Table 19. Ranking of Global Top Follicular Lymphoma Drugs Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Follicular Lymphoma Drugs Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Follicular Lymphoma Drugs, Headquarters and Area Served
Table 22. Global Key Players of Follicular Lymphoma Drugs, Products and Applications
Table 23. Global Key Players of Follicular Lymphoma Drugs, Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Follicular Lymphoma Drugs Market Size by Type (US$ Million), 2021–2026
Table 26. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2021–2026)
Table 27. Global Follicular Lymphoma Drugs Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2027–2032)
Table 29. Global Follicular Lymphoma Drugs Market Size by Administration Route (US$ Million), 2021–2026
Table 30. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2021–2026)
Table 31. Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (US$ Million), 2027–2032
Table 32. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2027–2032)
Table 33. North America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026
Table 35. North America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Follicular Lymphoma Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (US$ Million), 2027–2032
Table 48. Roche Company Details
Table 49. Roche Business Overview
Table 50. Roche Follicular Lymphoma Drugs Product
Table 51. Roche Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 52. Roche Recent Development
Table 53. Gilead Sciences Company Details
Table 54. Gilead Sciences Business Overview
Table 55. Gilead Sciences Follicular Lymphoma Drugs Product
Table 56. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 57. Gilead Sciences Recent Development
Table 58. Beigene Company Details
Table 59. Beigene Business Overview
Table 60. Beigene Follicular Lymphoma Drugs Product
Table 61. Beigene Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 62. Beigene Recent Development
Table 63. Bayer Company Details
Table 64. Bayer Business Overview
Table 65. Bayer Follicular Lymphoma Drugs Product
Table 66. Bayer Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 67. Bayer Recent Development
Table 68. Secura Bio Company Details
Table 69. Secura Bio Business Overview
Table 70. Secura Bio Follicular Lymphoma Drugs Product
Table 71. Secura Bio Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 72. Secura Bio Recent Development
Table 73. Epizyme Company Details
Table 74. Epizyme Business Overview
Table 75. Epizyme Follicular Lymphoma Drugs Product
Table 76. Epizyme Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 77. Epizyme Recent Development
Table 78. Eisai Company Details
Table 79. Eisai Business Overview
Table 80. Eisai Follicular Lymphoma Drugs Product
Table 81. Eisai Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 82. Eisai Recent Development
Table 83. Acrotech Biopharma Company Details
Table 84. Acrotech Biopharma Business Overview
Table 85. Acrotech Biopharma Follicular Lymphoma Drugs Product
Table 86. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 87. Acrotech Biopharma Recent Development
Table 88. Teva Company Details
Table 89. Teva Business Overview
Table 90. Teva Follicular Lymphoma Drugs Product
Table 91. Teva Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 92. Teva Recent Development
Table 93. Eagle Pharmaceuticals Company Details
Table 94. Eagle Pharmaceuticals Business Overview
Table 95. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product
Table 96. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 97. Eagle Pharmaceuticals Recent Development
Table 98. MundiPharma Company Details
Table 99. MundiPharma Business Overview
Table 100. MundiPharma Follicular Lymphoma Drugs Product
Table 101. MundiPharma Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 102. MundiPharma Recent Development
Table 103. Pfizer Company Details
Table 104. Pfizer Business Overview
Table 105. Pfizer Follicular Lymphoma Drugs Product
Table 106. Pfizer Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 107. Pfizer Recent Development
Table 108. Novartis Company Details
Table 109. Novartis Business Overview
Table 110. Novartis Follicular Lymphoma Drugs Product
Table 111. Novartis Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 112. Novartis Recent Development
Table 113. Bristol-Myers Squibb Company Details
Table 114. Bristol-Myers Squibb Business Overview
Table 115. Bristol-Myers Squibb Follicular Lymphoma Drugs Product
Table 116. Bristol-Myers Squibb Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 117. Bristol-Myers Squibb Recent Development
Table 118. JW Therapeutics Company Details
Table 119. JW Therapeutics Business Overview
Table 120. JW Therapeutics Follicular Lymphoma Drugs Product
Table 121. JW Therapeutics Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 122. JW Therapeutics Recent Development
Table 123. FOSUNKite Company Details
Table 124. FOSUNKite Business Overview
Table 125. FOSUNKite Follicular Lymphoma Drugs Product
Table 126. FOSUNKite Revenue in Follicular Lymphoma Drugs Business (US$ Million), 2021–2026
Table 127. FOSUNKite Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Follicular Lymphoma Drugs Picture
Figure 2. Global Follicular Lymphoma Drugs Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Follicular Lymphoma Drugs Market Share by Type: 2025 vs 2032
Figure 4. Anti-CD20 mAbs Features
Figure 5. Chemotherapy Agents Features
Figure 6. Kinase Inhibitor Features
Figure 7. Others Features
Figure 8. Global Follicular Lymphoma Drugs Market Size by Administration Route (US$ Million), 2021–2032
Figure 9. Global Follicular Lymphoma Drugs Market Share by Administration Route: 2025 vs 2032
Figure 10. Injection Case Studies
Figure 11. Oral Case Studies
Figure 12. Follicular Lymphoma Drugs Report Years Considered
Figure 13. Global Follicular Lymphoma Drugs Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 14. Global Follicular Lymphoma Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Follicular Lymphoma Drugs Market Share by Region: 2025 vs 2032
Figure 16. Global Follicular Lymphoma Drugs Market Share by Players in 2025
Figure 17. Global Follicular Lymphoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by Follicular Lymphoma Drugs Revenue in 2025
Figure 19. North America Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. North America Follicular Lymphoma Drugs Market Share by Country (2021–2032)
Figure 21. United States Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Canada Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Europe Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Follicular Lymphoma Drugs Market Share by Country (2021–2032)
Figure 25. Germany Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. France Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. U.K. Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Italy Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Russia Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Ireland Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Asia-Pacific Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Follicular Lymphoma Drugs Market Share by Region (2021–2032)
Figure 33. China Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Japan Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. South Korea Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Southeast Asia Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. India Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Australia & New Zealand Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Latin America Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Follicular Lymphoma Drugs Market Share by Country (2021–2032)
Figure 41. Mexico Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Brazil Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Middle East & Africa Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Follicular Lymphoma Drugs Market Share by Country (2021–2032)
Figure 45. Israel Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Saudi Arabia Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. UAE Follicular Lymphoma Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Roche Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 49. Gilead Sciences Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 50. Beigene Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 51. Bayer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 52. Secura Bio Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 53. Epizyme Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 54. Eisai Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 55. Acrotech Biopharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 56. Teva Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 57. Eagle Pharmaceuticals Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 58. MundiPharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 59. Pfizer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 60. Novartis Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 62. JW Therapeutics Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 63. FOSUNKite Revenue Growth Rate in Follicular Lymphoma Drugs Business (2021–2026)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
